Authors originally hoped that non-overlapping toxicities with the CHK1 inhibitor (mainly causing hematological effects) and PI3K/mTOR inhibition (primarily hyperglycemia and gastrointestinal effects) and a reduction in dose level would be tolerable. The gene discussed is PIK3CB; the disease is Hyperglycemia.